Key Takeaways:
- Doximity (DOCS) reported Q3 fiscal 2026 revenue of $185 million, beating analyst estimates of around $182 million and extending its multi-quarter streak of consensus beats.
- DOCS stock trades near $26, down around 40% year to date and approaching its 52-week low of $21.
- The near-term valuation model projects DOCS could rise from $26 to around $34 per share by March 2028, based on 10.1% revenue growth, 53% operating margins, and a 16.6x P/E multiple.
- That implies a 31% total return, or around 15.2% annualized over the next 1.9 years.
What Happened?
Doximity Inc. (DOCS) has been under persistent pressure in 2026 despite consistently beating analyst expectations at the top line. The company reported Q3 fiscal 2026 revenue of $185 million, which topped the consensus estimate of around $182 million and continued a long streak of quarterly beats.
But the stock slumped after management provided a weaker-than-expected outlook for Q4 fiscal 2026, raising concerns about near-term growth momentum. And in April 2026, CFO Anna Bryson resigned, with Chief Accounting Officer Siddharth Sitaram named as interim CFO. So leadership uncertainty compounded the growth concern and accelerated the year-to-date selloff.
Doximity is the largest online professional network for physicians and healthcare professionals in the United States. The platform lets doctors collaborate on patient cases, send HIPAA-compliant (secure, privacy-protected) messages, stay current on medical research, and manage their professional profiles, all within a single mobile and web application.
More than 80% of U.S. physicians are registered on the platform, giving Doximity a uniquely defensible position as medical media and professional infrastructure. The company generates revenue primarily by selling advertising and promotional solutions to pharmaceutical companies, health systems, and medical device firms that want to reach physicians.
In March 2026, Doximity published a report finding that 54% of physicians already use AI tools in their practice, but 71% cited accuracy concerns, pointing to a growing but cautious opportunity for AI integration into clinical workflows.
Despite near-term concerns, Doximity has delivered consistent earnings beats and maintains extraordinary unit economics. The LTM (last twelve months) EBIT margin stands at around 37.5%, and the gross margin reaches nearly 90%, reflecting a software-heavy, asset-light model that generates significant cash.
Here’s why Doximity stock could recover meaningfully as pharmaceutical advertising spending normalizes and AI-powered platform features deepen physician engagement at scale.
What the Model Says for DOCS Stock
We analyzed the upside potential for Doximity stock using valuation assumptions based on its dominant physician network, pharmaceutical advertising revenue recovery, and the expansion of AI-powered communication tools for healthcare professionals across its platform.
Based on estimates of 10.1% annual revenue growth, 53% operating margins, and a normalized P/E multiple of 16.6x, the model projects Doximity stock could rise from $26 to around $34 per share.
That would be a 31% total return, or a 15.2% annualized return over the next 1.9 years.
Our Valuation Assumptions
TIKR’s Valuation Model lets you plug in your own assumptions for a company’s revenue growth, operating margins, and P/E multiple, and calculates the stock’s expected returns.
Here’s what we used for DOCS stock:
1. Revenue Growth: 10.1%
Doximity delivered Q3 fiscal 2026 revenue growth of around 10% year-over-year. The company’s 3-year revenue CAGR stands at 18.4%, and the 2-year forward consensus CAGR sits at around 10.6%. Pharmaceutical advertising budgets are the primary revenue driver, and these tend to recover alongside new drug launch cycles. Doximity has beaten analyst revenue estimates in every reported quarter for several consecutive years.
Based on analysts’ consensus estimates, we used 10.1% annual revenue growth, reflecting Doximity’s ability to sustain double-digit growth as pharma advertising normalizes and AI-powered tools expand the platform’s utility for physicians.
2. Operating Margins: 53%
Doximity’s LTM operating margin stands at around 47.3%, and the 3-year average sits near 42.6%. The company operates a capital-light software platform with minimal cost of revenue and very low incremental costs to serve additional physicians. As revenue scales, operating leverage naturally drives margins higher over time.
Based on analysts’ consensus estimates, we used 53% operating margins, reflecting Doximity’s structural cost efficiency and the inherent scalability of its physician network, which functions as both the product and the moat of the business.
3. Exit P/E Multiple: 16.6x
Doximity currently trades at an NTM P/E of around 16.6x, down sharply from the 32x to 56x range seen in prior years. The lower multiple reflects both a deceleration in growth rates and near-term leadership uncertainty following the CFO departure. But consistent earnings delivery and a potential multi-year re-rating are possible if revenue growth reaccelerates.
Based on analysts’ consensus estimates, we use 16.6x as the exit multiple, reflecting a market that has meaningfully derated Doximity’s growth premium but where multiple re-expansion becomes plausible over a 2-year recovery horizon.
Build your own Valuation Model to value any stock (It’s free!) >>>
What Happens If Things Go Better or Worse?
Different scenarios for DOCS stock through 2034 show varied outcomes based on pharmaceutical advertising trends, physician platform engagement, and AI monetization (these are estimates, not guaranteed returns):
- Low Case: Pharma advertising budgets stay cautious, and growth continues to decelerate → around 3.1% annual returns
- Mid Case: Pharma advertising recovers steadily, and platform engagement holds at current levels → around 6.4% annual returns
- High Case: AI tools unlock new revenue streams, and pharmaceutical advertising rebounds strongly → around 9.4% annual returns
Going forward, DOCS stock carries a near-term model return of around 15.2% annually, making it one of the more notable setups among the five companies analyzed in this series if the underlying growth assumptions hold through the forecast horizon.
The CFO transition and weak Q4 guidance are genuine near-term overhangs, and the Q4 fiscal 2026 results expected on May 13, 2026, will serve as an important near-term catalyst for investors. But the fundamental case of a deeply embedded physician network, consistently high margins, and a deflated valuation multiple creates a meaningful asymmetry that long-term investors may find worth exploring carefully.
See what analysts think about DOCS stock right now (Free with TIKR) >>>
Should You Invest in Doximity?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up DOCS, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track DOCS alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Doximity stock on TIKR Free→
Looking for New Opportunities?
- See what stock billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
